Neurogene Inc. (NGNE) shares gained 11.74 percent to $21.99, up $2.31 on Friday, possibly after the company announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its investigational gene therapy NGN-401 for the treatment of Rett syndrome, the previous day.
The stock is currently trading at $21.99, compared with a previous close of $19.68. It opened at $22.96 and has traded between $20.50 and $23.29 during the session on the Nasdaq. Trading volume stands at 0.40 million shares, compared with an average volume of 0.16 million shares.
The designation was based on interim Phase 1/2 trial data demonstrating clinically meaningful and durable functional improvements across multiple Rett syndrome domains. The stock has traded in a 52-week range of $6.88 to $37.27.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.